FindTrial
Sign In

Use of controlled heated intravesical chemotherapy in urinary bladder cancer

Pilot study to evaluate safety and efficacy of single postoperative HIVEC after TURBT.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/02/040185
Enrollment
25
Registered
2022-02-10
Start date
Unknown
Completion date
Unknown
Last updated
2022-02-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N329- Bladder disorder, unspecified

Interventions

Intervention1: Hyperthermic intravesical mitomycin: Postoperative HIVEC will be given in all risk group within 24 hours of TURBT, preferably within 6 hours of TURBT. Control Intervention1: Not applica

Sponsors

Rajiv Gandhi Cancer Institute and Research Centre
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Post-operative hyperthermic intravesical mitomycin will be given in all patients of non muscle invasive bladder cancer.

Exclusion criteria

Exclusion criteria: 1. Patient having: - gross hematuria - bladder perforation - muscle invasive disease 2. Patient not willing to sign consent for the study

Design outcomes

Primary

MeasureTime frame
Incidence of adverse eventsTimepoint: Adverse events which occur within 30 days after the study intervention.—

Secondary

MeasureTime frame
to assess Recurrence free survival, Progression free survivalTimepoint: Every 3 monthly.—

Countries

India

Contacts

Public ContactDr Amitabh Singh

Rajiv Gandhi Cancer Institute and Research Centre

amitabhsingh27@gmail.com01147022065

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026